Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations
- 21 July 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Physical Chemistry Chemical Physics
- Vol. 23 (32) , 17576-17590
Abstract
The rational design of selective histone deacetylase 2 (HDAC2) inhibitors is beneficial for the therapeutic treatment of liver cancer, though HDAC2 is highly homologous to HDAC8, which may lead to undesired side effects due to the pan-inhibition towards HDAC2 and HDAC8. To clarify the structural basis of selective inhibition towards HDAC2 over HDAC8, we utilized multiple in silico strategies, including sequence alignment, structural comparison, molecular docking, molecular dynamics simulations, free energy calculations, alanine scanning mutagenesis, pharmacophore modeling, protein contacts atlas analysis and QM/MM calculations to study the binding patterns of HDAC2/8 selective inhibitors. Through the whole process described above, it is found that although HDAC2 has conserved GLY154 and PHE210 that also exist within HDAC8, namely GLY151 and PHE208, the two isoforms exhibit diverse binding modes towards their inhibitors. Typically, HDAC2 inhibitors interact with the Zn2+ ions through the core chelate group, while HDAC8 inhibitors adopt a bent conformation within the HDAC8 pocket that inclines to be in contact with the Zn2+ ions through the terminal hydroxamic acid group. In summary, our data comprehensively elucidate the selectivity mechanism towards HDAC2 over HDAC8, which would guide the rational design of selective HDAC2 inhibitors for liver cancer treatment.Keywords
Funding Information
- Department of Education of Liaoning Province (2020LJC05)
- Overseas Expertise Introduction Project for Discipline Innovation (D20029)
This publication has 35 references indexed in Scilit:
- A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related TestsPLOS ONE, 2013
- Epigenetic control of skull morphogenesis by histone deacetylase 8Genes & Development, 2009
- Histone Deacetylase Inhibitors: Overview and PerspectivesMolecular Cancer Research, 2007
- Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complexEMBO Reports, 2007
- Histone deacetylase inhibitors in cancer therapyExpert Opinion on Investigational Drugs, 2007
- HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeuticsCell Research, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- A Combined QM/MM Approach to Protein−Ligand Interactions: Polarization Effects of the HIV-1 Protease on Selected High Affinity InhibitorsJournal of Medicinal Chemistry, 2004
- Acetylation of proteins as novel target for antitumor therapy: Review articleAmino Acids, 2004
- Insights into Protein–Protein Binding by Binding Free Energy Calculation and Free Energy Decomposition for the Ras–Raf and Ras–RalGDS ComplexesJournal of Molecular Biology, 2003